FLT3 Bid 'Astellas' Promising as Before: Ambit Raises $50M

At least a year shy of the next milestone payment from partner Astellas Pharma Inc., Ambit Biosciences Inc. raised $50 million from existing investors to advance quizartinib in acute myelogenous leukemia (AML).